#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
Endpoints NewsTopic alignment 86
Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like heart attacks and strokes. If the ...
Filed under
- GLP-1 cost managementmatch 86
How to measure the long-term value of GLP-1s within employer healthcare costs
HFMATopic alignment 92
Medicare Plans Rarely Cover Anti-Obesity Drugs for Other FDA-Approved Purposes
USC SchaefferTopic alignment 95
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
MedCity NewsTopic alignment 86
EqualityGLP-1 Weight-Loss Drugs Will Be Covered for Fewer US EmployeesJust 53% of US employers now cover GLP-1s for weight loss, and nearly a third of those still offering the benefit are considering dropping it.Read more
BloombergTopic alignment 90